Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Korosho Invites Applicants for Development of Diaminopyridine
August 30, 2010
- Anti-IL-6 Receptor Antibody Effective for IBD: NIBIO, Osaka Univ.
August 30, 2010
- Rohto: Sales Down due to Slump of Pollinosis, Metabolic Syndrome-Related Products
August 30, 2010
- Teijin: Maintains Top Market Share for Osteoporosis Drugs
August 30, 2010
- Canakinumab, KW-0761 Designated as Orphan Drugs
August 30, 2010
- Vectibix Fails to Prolong OS in Head and Neck Cancer
August 30, 2010
- Pfizer Applies for Its 1st Generics Aiming at Listing in 2011
August 30, 2010
- Meiji Seika: Sales Up 16.6% Driven by New Drugs
August 30, 2010
- All Applicants Should Be Given Access to Prior Assessment System: JPMA
August 30, 2010
- Terumo: Sales Up 4.9% Driven by Strong Overseas Sales
August 30, 2010
- Fujitsu Aims at 30% Market Share with Cloud Services for Pharma Industry
August 30, 2010
- Asahi Kasei Pharma: Sales Down for Mainstay Products
August 30, 2010
- 80% of Oncologists Conduct KRAS Gene Test: Merck Serono
August 30, 2010
- Miraca HD: Sales Up 10.4% to ¥41.4 Bil.
August 30, 2010
- Torii: Anti-HIV Drug Props Up Business
August 30, 2010
- Korosho to Promote Sharing of Knowhow on Use of Generics
August 30, 2010
- Takara Bio: Gene Engineering Segment Struggles
August 30, 2010
- Yakult: Elplat's Sales Up 31.4%
August 30, 2010
- Sawai: Sales to Dispending Pharmacies Up 59.2%
August 30, 2010
- A&T: Acquisition of ATWill Boosts Sales of In Vitro Diagnostics
August 30, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…